SCHEMBL5111921

SCHEMBL5111921

Cc1cc(/C(O)=C/c2ccnc(NC(=O)O)n2)ccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.41
GRM4 Q14833 1/20 0.37
PIM1 P11309 1/20 0.37
KMT2A Q03164 4/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CAMKK2 Q96RR4 2/20 0.35
GSK3B P49841 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CTNNB1 P35222 1/20 0.35
TCF7L2 Q9NQB0 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MAPK13 O15264 2/20 0.34
MAPK12 P53778 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111926 1.00 MAPK14 (0.41) MAPK14GRM4PIM1KMT2ANPC1
SCHEMBL5119342 0.87 AAK1 (0.37) MAPK14GRM4HDAC3HDAC1HDAC2
SCHEMBL5126091 0.69 AAK1 (0.38) MAPK14GRM4KMT2ANPC1RAB9A
SCHEMBL5126085 0.69 AAK1 (0.38) MAPK14GRM4KMT2ANPC1RAB9A
SCHEMBL20447282 0.66 AAK1 (0.43) MAPK14KMT2ANPC1POLBRAB9A
SCHEMBL2093087 0.66 PIM1 (0.40) PIM1RAB9AALDH1A1HDAC1HDAC6
SCHEMBL15881328 0.65 L3MBTL1 (0.55) KMT2ANPC1POLBRAB9ASMN1; SMN2
SCHEMBL385343 0.64 LMNA (0.53) PIM1KMT2APOLBRAB9ASMN1; SMN2
SCHEMBL309585 0.64 KCNQ3 (0.40) KMT2ANPC1POLBRAB9ASMN1; SMN2
SCHEMBL309586 0.64 KCNQ3 (0.40) KMT2ANPC1POLBRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof MAPK13, MMP13, MAPK3 MAPK14 5/4885GRM4 2185/4885PIM1 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.